国内外缺铁性贫血药物治疗的安全性和有效性研究进展

doi:10.19803/j.1672-8629.20210837

摘要/Abstract

摘要： 对于治疗缺铁性贫血,近年来国内外不断有新的铁剂出现。枸橼酸铁用于治疗慢性肾病患者的缺铁性贫血;麦芽酚铁用于治疗炎症性肠病以及对于其他口服铁剂无效的缺铁性贫血患者。新型静脉铁剂主要为大剂量铁剂,如超顺磁氧化铁、异麦芽糖酐铁、羧基麦芽糖铁,可快速改善患者贫血症状,在伴有慢性肾病、心力衰竭、炎症性肠病等缺铁性贫血患者中更具优势。本文通过对于最近几年国内外铁剂的有效性和安全性以及补铁机制展开研究,为缺铁性贫血患者临床安全、有效地使用提供循证依据。

关键词: 缺铁性贫血, 铁剂, 麦芽酚铁, 循证药学评价, 安全性, 有效性

Abstract: In recent years, there have been new types of iron preparations for the treatment of iron-deficiency anemia at home and abroad. Ferric citrate is used for iron-deficiency anemia in patients with chronic kidney disease while ferric maltol is used for iron-deficiency anemia in patients with inflammatory bowel disease and patients who do not respond to other oral iron preparations. New intravenous irons are mainly high-dose iron preparations, such as ferumoxytol, iron isomaltoside, ferric carboxymaltose, which can rapidly improve the symptoms of anemia, and show more advantages in patients with chronic kidney disease, heart failure, inflammatory bowel disease. This article outlines the effectiveness and safety of iron formulations and the mechanism of iron supplementation at home and abroad in order to provide evidence-based evidence for safe and effective use of iron-deficiency anemia.

Key words: iron deficiency anemia, iron preparations, ferric maltol, evaluation of evidence-based pharmacy, safety, effectiveness

中图分类号:

蔡乐乐, 张卓琳, 李歆, 方丹君, 韩峰. 国内外缺铁性贫血药物治疗的安全性和有效性研究进展[J]. 中国药物警戒, 2022, 19(11): 1262-1265.

CAI Lele, ZHANG Zhuolin, LI Xin, FANG Danjun, HAN Feng. Research progress in safety and effectiveness of medication of iron deficiency anemia[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1262-1265.

参考文献

[1] Chinese Medical Association Hematology Branch Red Blood Cell Disease (Anemia) Group. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia[J]. National Medical Journal of China(中华医学杂志), 2018, 98(28): 2233-2237.
[2] CAMASCHELLA C.Iron deficiency[J]. Blood, 2019, 133(1): 30-39.
[3] PATEL D, TRIVEDI C, KHAN N.Management of anemia in patients with inflammatory bowel disease (IBD)[J]. Curr Treat Options Gastroenterol, 2018, 16(1): 112-128.
[4] MURAWSKA N, FABISIAK A, FICHNA J.Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment[J]. Inflamm Bowel Dis, 2016, 22(5): 1198-1208.
[5] BAYRAKTAR UD, BAYRAKTAR S.Treatment of iron deficiency anemia associated with gastrointestinal tract diseases[J]. World J Gastroenterol, 2010, 16(22): 2720-2725.
[6] NIELSEN OH, AINSWORTH M, COSKUN M, et al.Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review[J]. Medicine(Baltimore), 2015, 94(23): e963.
[7] SHIM JY, KIM MY, KIM YJ, et al.Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women[J]. BMC Pregnancy Childbirth, 2018, 18(1): 349.
[8] VANOBBERGHEN F, LWENO O, KUEMMERLE A, et al.Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial[J]. Lancet Glob Health, 2021, 9(2): e189-e198.
[9] WOMACK R, BERRU F, PANWAR B, et al.Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial[J]. Clin J Am Soc Nephrol, 2020, 15(9): 1251-1258.
[10] TOLKIEN Z, STECHER L, MANDER AP, et al.Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(2): e0117383.
[11] GANZ T, BINO A, SALUSKY IB.Mechanism of action and clinical attributes of auryxia(R) (ferric citrate)[J]. Drugs, 2019, 79(9): 957-968.
[12] FISHBANE S, BLOCK GA, LORAM L, et al.Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia[J]. J Am Soc Nephrol, 2017, 28(6): 1851-1858.
[13] WOMACK R, BERRU F, PANWAR B, et al.Effect of ferric citrate versus ferrous sulfate on iron and phosphate parameters in patients with iron deficiency and CKD: a randomized trial[J]. Clin J Am Soc Nephrol, 2020, 15(9): 1251-1258.
[14] HU C, ZHANG XG.Ferric maltol[J]. Chinese Journal of Medicinal Chemistry(中国药物化学杂志), 2020, 30(4): 257.
[15] GASCHE C, AHMAD T, TULASSAY Z, et al.Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program[J]. Inflamm Bowel Dis, 2015, 21(3): 579-588.
[16] SCHMIDT C, AHMAD T, TULASSAY Z, et al.Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study[J]. Aliment Pharmacol Ther, 2016, 44(3): 259-270.
[17] CUMMINGS J F, FRASER A, STANSFIELD C, et al.Ferric maltol real-world effectiveness study in hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK[J]. BMJ Open Gastroenterol, 2021, 8(1): e000530.
[18] HOWALDT S, DOMÈNECH E, MARTINEZ N, et al. Long-term effectiveness of oral ferric maltol vs intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: a randomized controlled noninferiority trial[J]. Inflamm Bowel Dis, 2022, 28(3): 373-384.
[19] PERGOLA PE, FISHBANE S, GANZ T.Novel oral iron therapies for iron deficiency anemia in chronic kidney disease[J]. Adv Chronic Kidney Dis, 2019, 26(4): 272-291.
[20] PERGOLA PE, KOPYT NP.Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension[J]. Am J Kidney Dis, 2021, 78(6): 846-856.
[21] KUMAR A, SHARMA E, MARLEY A, et al.Iron deficiency anaemia: pathophysiology, assessment, practical management[J]. BMJ Open Gastroenterology, 2022, 9(1): e000759.
[22] COHEN J, KHUDANYAN A, LU J, et al.A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency[J]. Am J Hematol, 2020, 95(12): 1572-1577.
[23] MACDOUGALL IC, STRAUSS WE, DAHL NV, et al.Ferumoxytol for iron deficiencyanemia in patients undergoing hemodialysis. The FACT randomized controlled trial[J]. Clin Nephrol, 2019, 91(4): 237-245.
[24] AUERBACH M, CHERTOW GM, ROSNER M.Ferumoxytol for the treatment of iron deficiency anemia[J]. Expert Rev Hematol, 2018, 11(10): 829-834.
[25] PANTH N, PAUDEL KR, PARAJULI K.Reactive oxygen species: a key hallmark of cardiovascular disease[J]. Adv Med, 2016, 2016: 9152732.
[26] DERMAN R, ROMAN E, MODIANO MR, et al.A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia[J]. Am J Hematol, 2017, 92(3): 286-291.
[27] AUERBACH M, HENRY D, DERMAN RJ, et al.A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial[J]. Am J Hematol, 2019, 94(9): 1007-1014.
[28] SCOTT LJ.Ferric carboxymaltose: a review in iron deficiency[J]. Drugs, 2018, 8(4): 479-493.
[29] ADKINSON NF, STRAUSS WE, MACDOUGALL IC, et al.Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial[J]. Am J Hematol, 2018, 93(5): 683-690.
[30] WOLF M, RUBIN J, ACHEBE M, et al.Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials[J]. JAMA, 2020, 323(4): 432-443.
[31] WOLF M, CHERTOW GM, MACDOUGALL I C, et al.Randomized trial of intravenous iron-induced hypophosphatemia[J]. JCI Insight, 2018, 3(23): e124486.
[32] LOPEZ A, CACOUB P, MACDOUGALL IC, et al.Iron deficiency anaemia[J]. Lancet, 2016, 387(10021): 907-916.
[33] BAYRAKTAR UD, BAYRAKTAR S.Treatment of iron deficiency anemia associated with gastrointestinal tract diseases[J]. World J Gastroenterol, 2010, 16(22): 2720-2725.
[34] MULDER MB, VAN DEN HOEK HL, BIRNIE E, et al. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (monofer^®) versus ferric carboxy-maltose (ferinject^®). A single center, cohort study[J]. Br J Clin Pharmacol, 2019, 85(2): 385-392.